Beacon’s pivotal VISTA trial met its endpoint in inherited vision loss, with low-light gains and surgical risks shaping the next questions. Telix’s $1.65 billion ITM deal combines isotope supply with an investigational cancer therapy facing manufacturing hurdles. Novo’s CagriSema result in diabetes, Cue’s chronic-hives data and Insmed’s ARIKAYCE (amikacin liposome inhalation suspension) review show different evidence and regulatory paths. FDA opens clearer routes for validated non-animal methods, while a Wednesday panel will examine GRAIL’s Galleri cancer-screening claims.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →